Universal Beteiligungs und Servicegesellschaft mbH Has $30.18 Million Position in Natera, Inc. $NTRA

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Natera, Inc. (NASDAQ:NTRA) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,702 shares of the medical research company’s stock after selling 8,100 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Natera were worth $30,184,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in NTRA. Horizon Investments LLC bought a new stake in Natera in the third quarter valued at approximately $32,000. Sound Income Strategies LLC boosted its holdings in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the last quarter. Flagship Harbor Advisors LLC bought a new stake in Natera in the fourth quarter valued at approximately $41,000. Quent Capital LLC bought a new stake in Natera in the third quarter valued at approximately $46,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Natera in the fourth quarter valued at approximately $62,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on NTRA shares. Wells Fargo & Company upped their target price on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. TD Cowen restated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Robert W. Baird increased their price target on Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $253.47.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $202.30, for a total transaction of $606,900.00. Following the sale, the insider directly owned 147,882 shares in the company, valued at $29,916,528.60. The trade was a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Burkes Brophy sold 785 shares of Natera stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total value of $160,242.05. Following the sale, the chief financial officer owned 63,354 shares in the company, valued at $12,932,452.02. The trade was a 1.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 138,257 shares of company stock valued at $31,468,797. 5.63% of the stock is currently owned by company insiders.

Natera Stock Down 3.2%

NTRA stock opened at $201.14 on Friday. The firm has a market cap of $28.51 billion, a PE ratio of -131.46 and a beta of 1.68. The business has a 50 day moving average of $202.94 and a 200-day moving average of $212.66. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the previous year, the firm earned ($0.41) earnings per share. On average, research analysts expect that Natera, Inc. will post -1.71 earnings per share for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.